Infinity named to NASDAQ Global Select Market

NewsGuard 100/100 Score

Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) announces that, effective today, it has been named to the NASDAQ Global Select Market tier, the premier listing tier for NASDAQ companies. The NASDAQ Global Select Market tier was created in July 2006 for companies that meet the highest listing standards in the world, based on financial and liquidity requirements.

"We are delighted by the recognition of our financial strength and by the fact that Infinity stock will now be trading on the top tier of the NASDAQ Stock Market," stated Adelene Q. Perkins, president and chief executive officer of Infinity. "Our strong financial profile enables us to advance a broad portfolio of product candidates that have the potential to meaningfully impact patients' lives, and thereby create long-term value for shareholders."

Following elevation to the NASDAQ Global Select Market, the company's ticker symbol remains INFI. Infinity shares previously traded on the NASDAQ Global Market. Currently, NASDAQ-listed companies are classified under three listing tiers – NASDAQ Global Select Market, NASDAQ Global Market, and NASDAQ Capital Market.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Lancet Commission predicts sharp increase in global prostate cancer cases